Welcome to our dedicated page for Amarin Plc news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin Plc stock.
Amarin Corporation Plc (NASDAQ: AMRN) is a pioneering biopharmaceutical company dedicated to improving cardiovascular health through the development and commercialization of innovative therapeutic products. The company's flagship product, VASCEPA® (icosapent ethyl), is designed to address cardiovascular risks and has received FDA approval in the United States as well as marketing authorization in Europe under the brand name VAZKEPA®.
Amarin's mission is to advance scientific understanding and provide effective treatments for high-risk cardiovascular patients who have not adequately responded to traditional therapies. VASCEPA, a unique form of eicosapentaenoic acid (EPA), has been shown in clinical trials to significantly reduce cardiovascular events, offering a new therapeutic option for patients with elevated triglyceride levels.
In recent years, Amarin has undertaken strategic initiatives to bolster its market presence and financial stability. Notable accomplishments include:
- Leadership Restructure: In 2023, Amarin appointed new executives, including President & CEO Patrick Holt, to drive the company's global strategy and operational improvements.
- Revenue Growth in Europe: Amarin reported approximately 65% growth in in-market sales in Europe for Q1 2024 compared to Q4 2023, with significant progress in Spain and the UK.
- Financial Discipline: The company has implemented measures to reduce operating expenses and preserve cash, closing 2023 with $321 million in cash and no debt.
- Share Repurchase Plan: In early 2024, Amarin announced a share repurchase plan of up to $50 million to enhance shareholder value, pending necessary approvals.
Amarin's commitment to cardiovascular health extends globally, with operations in the United States, Europe, and partnerships in Canada, China, and other regions. The company continues to explore new market opportunities and strengthen its intellectual property portfolio, as evidenced by the recent extension of VAZKEPA's patent protection in Europe until 2039.
For more information, visit www.amarincorp.com and the dedicated VASCEPA site at www.vascepa.com.
News
Rhea-AI Summary
Amarin Corporation plc (AMRN) reports total revenues of $75 million in Q4 and $306 million for full-year 2023. They reaffirm a year-end cash position of $321 million and a positive cash flow of $10 million for 2023. The company plans to execute a share repurchase program of up to $50 million by Q2 2024. Despite a decrease in net product revenue, Amarin remains focused on building momentum in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.94%
Tags
-
Rhea-AI Summary
Amarin Corporation plc (AMRN) will host a conference call to discuss its fourth quarter and year-end 2023 results on February 29th, 2024. The call will include a Q&A session and highlights from 2023. Shareholders can submit questions through Say Technologies for the earnings call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
-
Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) announced a letter to shareholders highlighting significant actions taken to strengthen the company, including leadership restructuring, operational improvements, and financial discipline. The company's focus on extending market leadership in the U.S., accelerating revenues in Europe, and advancing market access in the Rest of World (RoW) positions it for shareholder value in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
Rhea-AI Summary
Amarin Corporation plc (AMRN) reported unaudited total revenues of $72-74 million in Q4 2023, ending the year with a cash position of $321 million and delivering full-year positive cash flow of ~$10 million. The company's 2024 priorities include accelerating revenue in key European launch markets, retaining IPE market leadership in the US, and maximizing patient uptake in Rest of World (RoW) through partnerships. Amarin also announced a plan to initiate a share repurchase program of up to $50 million. The company will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.99%
Tags
-
Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) is set to participate in the 42nd Annual JP Morgan Healthcare Conference, with President and CEO Patrick Holt scheduled to present on January 10, 2024. The webcast of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
-
News
Rhea-AI Summary
Sarissa Capital Management LP (Sarissa) issued a statement regarding Amarin Corporation plc (NASDAQ: AMRN), expressing belief in the significant undervaluation of Amarin's stock. Sarissa remains a long-term shareholder and has been purchasing shares at depressed prices, never having sold any shares. The company has made progress in reorganizing its leadership team, streamlining its U.S. business, reworking Europe's commercial infrastructure, achieving national reimbursement approvals and launches of Vazkepa in Europe and securing international partnership deals. Sarissa acknowledges that turning around companies takes time and is pleased with Amarin's progress, expecting the value to be reflected in the stock price over time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) announced findings from new REDUCE-IT analyses, revealing that VASCEPA/VAZKEPA significantly reduced the risk of first and total cardiovascular events in a subgroup of statin-treated patients with Metabolic Syndrome but without diabetes. The results were presented at the American Heart Association Scientific Sessions 2023 and simultaneously published in the European Heart Journal Open. The findings support IPE as an important therapeutic option for patients with Metabolic Syndrome at high cardiovascular risk.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Amarin Corporation reported total net revenues of $66 million in the third quarter of 2023. They achieved positive cash flow of $8 million, marking the fifth consecutive quarter of cash positive operations. The company's quarter-ending cash position was $321 million. Amarin continues to deliver significant U.S. profit through the extended lifecycle and market leadership of their branded product VASCEPA®. They have also made progress with the early launch of VASCEPA® in European countries driven by new leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Amarin Corporation plc has appointed Jonathan Provoost as its new Executive Vice President, Chief Legal & Compliance Officer. Provoost brings over 20 years of corporate legal experience, having served in various leadership roles in pharmaceutical companies. He will join Amarin on November 15.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
Rhea-AI Summary
Amarin announces new research from the REDUCE-IT trial on the effects of VASCEPA/VAZKEPA in high-risk patient subgroups. The research includes reduction in CV events in patients with Metabolic Syndrome but without diabetes, mechanistic analyses of EPA and DHA, and demographic/clinical characteristics of US patients with diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
FAQ
What is the current stock price of Amarin Plc (AMRN)?
The current stock price of Amarin Plc (AMRN) is $0.5249 as of November 21, 2024.
What is the market cap of Amarin Plc (AMRN)?
The market cap of Amarin Plc (AMRN) is approximately 215.5M.
What does Amarin Corporation do?
Amarin Corporation is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, primarily through its product VASCEPA® (icosapent ethyl).
What is VASCEPA®?
VASCEPA® (icosapent ethyl) is Amarin's FDA-approved product designed to reduce cardiovascular events in high-risk patients by lowering triglyceride levels.
How did Amarin perform financially in recent quarters?
In Q1 2024, Amarin reported total net revenue of $56.5 million, with significant growth in Europe and a stable cash position of $308.2 million.
What recent strategic initiatives has Amarin undertaken?
Amarin has restructured its leadership, reported strong sales growth in Europe, implemented financial discipline measures, and announced a share repurchase plan.
What are the key markets for Amarin's products?
Amarin's key markets include the United States, Europe, Canada, China, and other regions, with ongoing efforts to expand market access and commercialization globally.
What recent achievements have boosted Amarin's market position?
Recent achievements include extending VAZKEPA's patent protection in Europe until 2039 and securing approximately 65% growth in in-market sales in Europe for Q1 2024.
How does VASCEPA® benefit patients?
VASCEPA® has been shown to significantly reduce cardiovascular events in high-risk patients with elevated triglyceride levels, offering a new treatment option beyond traditional therapies.
Who are the key executives at Amarin?
Key executives include President & CEO Patrick Holt, who brings global leadership and turnaround experience to drive the company's strategic initiatives.
What is the purpose of Amarin's share repurchase plan?
The $50 million share repurchase plan aims to enhance shareholder value by buying back shares, subject to necessary approvals.
How does Amarin support its global operations?
Amarin supports its global operations through offices in the United States, Ireland, Switzerland, and partnerships with commercial entities in various regions.
Amarin Corp Plc
Nasdaq:AMRN
AMRN Rankings
AMRN Stock Data
215.54M
404.75M
1.6%
17.05%
4.36%
Drug Manufacturers - General
Pharmaceutical Preparations
United States of America
DUBLIN 2